Comparative Pharmacology
Head-to-head clinical analysis: LAROTID versus PENTIDS 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAROTID versus PENTIDS 400.
LAROTID vs PENTIDS '400'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
Penicillin G binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking, leading to cell lysis.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
400 mg orally every 6 hours.
None Documented
None Documented
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
0.5-1 hour in patients with normal renal function. Prolonged to 2-5 hours in renal impairment, requiring dose adjustment.
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Primarily renal (tubular secretion and glomerular filtration); 60-90% of dose excreted unchanged in urine within 24 hours. Minor biliary excretion (<10%) and fecal elimination.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic